Jed, you, everyone. hello, and Thank
to call side. the As if the in the haven’t recording already. IIb results of RA read had October you progress Phase provide the always, I in to you the the the encourage do updates And described I’m the interim participate XX, and detail listen happy chance We from so positive analysis. recently trial on of clinical with the in and call from today’s to you transcript to or
seven of first Remember we imaging prior of our the and in of healthy validate planned in the this Active total stability and III. have and through Phase At this calculations three-arm readout data our over are the time, arms arm, sites Phase our enrolled we half are the in evaluating repeatability, we III tilmanocept the obtain mirroring in reproducibility enable study. for us study, upcoming to XXX that in RA, two order subjects this both to subjects study with third over patients help to
and that results our This in variability demonstrating with XXm within is in to provide involved RA can can on technology RA. and quantitative and of imaging, two the reproducible interim imaging time. positive, successful stable, inflammation. imaging and patients controls The tilmanocept technetium with is very RA product joints fundamentally define and advancing active important low a data and into without both this were that first over day arms Those demonstrated robust healthy
imagine, results, the potential been we’ve you these can so are we discussing partners. And with delighted as and with data
As and have Jed would been received. well data the you as mentioned, expect,
trial patients well enroll into of Phase Phase with and the IIb are as planning to from the III. We the for study RA of comparative joints histopathology start through will continue as readout of our this imaging the
are well II into right IIb and are that been so ongoing will recruitment positioned We – Phase already logistics will have III, the Phase sites our be and the currently for strategies the rolled recruiting since of the established. for that most into trial,
press our research the seen announcing release Inc. agreement morning, this IMV with collaboration have from might You
combinatory immuno-oncology they of along our cancer. The running types collaboration and stage publications clinical to proprietary efficacy have are I’d targeting macrophage their evaluate is with conduct cell-activating to of companies between evaluating to preclinical the platform. encourage IMV’s Meaning, two effect our immunotherapy look against more activated detail. trials, you the website for their their are purpose studies and this case, clinical of company. run they T of self-described, IMV in As this that different compounds, visit at
IMV would portion macrophages body’s self-defense which effect. the we to helps course, including combination a part cells tumors those the that of the tumors. cells. to are known target has body’s through T through surround a of resistance tumor’s of that and briefly, and therapeutic the But agent should own targets system, network form activate And tumor enhance and By immune our can activation the body’s the that aforementioned we see of otherwise cells removal of tumor actively antitumor a T then system therapeutic, of to our significant believe attack T own the IMV’s agent, cells, the
this IMV’s work a hope our towards we a that at of our to NIH end, just powerful therapy advance other treating organization, combination upon including collaboration these performed of approach increased variety containing we From targeted funded that provide first work studies could us builds CDXXX this we done, our combination efficacy this have recently to T-cell lead activation in new of therapeutics contract used Award. chemotherapeutic, by Therapeutics a And to constructs hypothesized cancers. therapeutic research evidence external our an Manocept demonstrating when with goal. We will with
years think that or three last We several the constructs that the efficacy accruing data the strongly have improve directed over many targeted most two our of therapies to And therapeutic types. been supportive indeed, against of we cancers. types can are of possibly idea
so natural And regarding potential additional that space. agreement And funding that cannot is senior we agreement cancer be additive This paves other with also a I confidentiality could some our after non-exclusive while grant rounds the that their way meaning synergistic data a therapeutics technology, We free of to can sharing the it compelling this or allocated agreement treatment. initiatives. terms conversations to the those spending a combined with for beyond here say IMV’s at that for time, of our them. technologies on fit are seemed leadership, towards we not under there money an therapeutics great data the pursue with possible are I this agreed And in collaboration of discuss arrangement, collaborations. into get initiatives IMV’s collaborations it effect believe and for was
that II you of subjects patient in pleased I’m NIH-funded in tell study and now imaging all our Phase to have completed Kaposi we enrollment sarcoma.
have of safety injection the of by evaluation with and intravenous subcutaneous in a and HIV doses we to TcXXm comparison done this title trial, outlined escalating an KS. injection of diagnosed tilmanocept study’s As patients in the
receptor Cells express that might You recall technology the our targets. that CDXXX KS
sense as to images up patients. well from as enrollment, of seeing as the with excellent we’re as in people, and hope detailed Qualitatively, a remains of it well an as lesions path imaging both discussion subject long. as U.S. and we the diagnostic and FDA following what both as indication we evaluation perspective open visualization KS is KS pursue on And With wrap and too throughout about the up, of it these impact and localization Africa. sNDA therapeutics HIV-infected full well can continued the it perspective, so a makes the now particular, in an has to analysis the of completion in lymphatics before
study We Boston. also in MGH have the ongoing atherosclerotic at plaque imaging
tilmanocept technetium continuing HIV-infected is for of funds This enriched patients study run this macrophages. to there to them this upon atherosclerotic score supportive Framingham we matched investigator-initiated plaques Grinspoon detect look activated building supportive provided of with provided Dr. and is to Risk the the that at in with controls. work healthy we published that evidence ability
We the study track in have of line a patients. next in team, discussions the that the that his data discussion of excellent and are signal update at can expected weeks. in provide steps. the we The supportive days hypothesis of and with soft published him read detailed and plaque orders we background with of tilmanocept far to an will to And they completion of, earlier are coming time, milestone work have so-called, thus an on have seen in with internal regular the
collaboration to next the indications I NIH, the course, steps, work plans recently of with will University FDA aligns, Phase shortly. and of and grant preclinical the National technology speak a looking also PET Work at of for Gallium imaging with part Lung our tilmanocept small transfer has with Birmingham, plaques. already cardiovascular we’ll that Gallium-XX Alabama, This studies in received to with making from Blood be agent discussing of the Heart, tilmanocept Institute disease. support our begun As begin about atherosclerotic business
compared to As We macrophages quarter. which in one enable as two has portfolio but applications in our test imaging continuing this to looking plaque, us filed we imaging, PET this will in project atherosclerosis tilmanocept deficiencies our patent outlined existing to FXX have also with and believe just to at IP last provisional significant studied widely agent expand FDG pipeline press comparison a tilmanocept new PET of We’re and method fits we our a in this, release and about
FDA, are be just another therapeutics we The the fundamentally file first of on largely therapeutic we patents pipeline update. four on Those January, makes on end. and relates second touch to the pipeline. that both our and and moving to and the the continue we highlights of of towards diagnostic the will focused could some last other a remain advance submission year’s before side wanted support our and that This this RA for to quarter total therapeutics these push progress to the of We filed likely the diagnostic for important indications. for and since provisional while
thank clinical research all always, moving team academic work. trial As absolutely to for of keep to the tireless I hard for want their things you. network Thank collaborators of and our and efforts their sites here
I Now turn back call to would over Jed? Jed. the like to
